Cancer R&D 2024 has wrapped up successfully. We’re grateful for your interest and interaction with Alfa Cytology. We’re eager to continue providing our expertise in cancer drug development. Let’s look back on these memorable moments!
Learn More
Alfa Cytology offers comprehensive drug development services specifically tailored to address the challenges of Adult T-cell Leukemia (ATL). With our expertise in biomedical research and commitment to advancing therapeutic options, we provide cutting-edge solutions to accelerate the development of effective treatments for ATL.
The precise mechanism underlying HTLV-1-induced malignancy remains incompletely understood. Chronic HTLV-1 infection is considered the initial crucial event in a multistep oncogenic process. Activation of the viral promoter leads to alterations in cellular pathways, including an autocrine loop involving IL-2, IL-15, and their receptors. This ultimately initiates ATL and leukemia development. The viral genes Tax and HBZ play pivotal roles in viral transcription and promoting T-cell proliferation. The diagram below depicts cellular proliferation after HTLV-1 infection in vivo.
Fig. 1. Propagation of HTLV-1-infected cells. (Yasunaga, J., 2020)
ATL occurs in HTLV-1 endemic regions: southwestern Japan, Caribbean Islands, Central/South America, tropical Africa, and the Middle East. Japan has 1.1 million carriers, globally 5-10 million. About 1,000 deaths from ATL occur annually in Japan. Current treatment is unsatisfactory, but lenalidomide or mogamulizumab shows promise for refractory/relapsed cases. Targeted therapies, including arsenic/interferon, monoclonal antibodies, and epigenetic therapy, require further clinical research.
Fig. 2. Therapeutic strategy for ATL. (Cook, L.B.; Phillips A A., 2021)
The standard treatment strategies for ATL are watchful waiting for indolent ATL, conventional chemotherapy, a combination of two antiviral drugs, and allogeneic hematopoietic stem cell transplantation (HSCT). Chemotherapy or antiviral treatment regimens are typically employed as first-line therapy for aggressive subtypes of ATL.
| Therapeutic strategies | Description |
|---|---|
| Antiviral therapy | AZT/IFN has been demonstrated to be highly effective in the chronic and smoldering subtypes of ATL, as well as in the acute subtype subgroup with wild-type P53, leading to a significant improvement in survival rates. |
| Chemotherapy | In Japan, the VCAP-AMP-VECP combination is presently an established chemotherapy regimen for treating aggressive ATL. In the United States, other suggested alternative regimens comprise dose-adjusted EPOCH, CHOP, hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone. |
| Watch and Wait Policy | Favorable ATL subtypes (chronic or smoldering) are closely monitored without chemotherapy, except for topical therapy for cutaneous lesions. This helps detect progression towards unfavorable subtypes. |
| HSCT | In contrast to autologous HSCT, allogeneic HSCT represents a crucial curative treatment option for patients with aggressive ATL. |
The present management approaches for aggressive ATL subtypes yield unsatisfactory results. The absence of a curative therapy and the low survival rates necessitate the exploration of novel targeted treatments to enhance survival and achieve a cure for ATL patients. The following table showcases some drugs currently under development for ATL.
| Drugs | Phase | Target |
|---|---|---|
| valemetostat | Enhancer of Zeste Homolog (EZH) 1/2 | |
| Anti-CCR4 Monoclonal Antibody KW 0761 | CCR4 | |
| Romidepsin CHOP | Histone deacetylase | |
| Carfilzomib, Romidepsin | Proteasome |
Vaccines for Adult T-cell Leukemia
Recent studies have indicated that anti-ATL vaccines hold potential as therapeutic options for ATL. The Tax-DC vaccine aims to enhance Tax-specific cytotoxic T lymphocyte (CTL) responses. Clinical trials are currently underway. Another candidate therapeutic vaccine for ATL is known as THV02, which consists of two lentiviral vectors for prime-boost strategies. THV02 has been shown to induce cellular responses in animal models and requires clinical trials to test its efficacy.
Our oncology and immuno-oncology experts advance drug candidates discovery, providing data-driven insights to enable the development of oncology treatments against ATL.
Alfa Cytology possesses vast expertise in HTLV-1 virus detection method development and the advancement of antiviral therapeutics. Leveraging our in-depth knowledge of the pathophysiology of ATL, we provide a wide range of services focused on developing therapeutic approaches specifically tailored for ATL. If you have a project in this field or are interested in ATL, we encourage you to contact us for further information.
References